Compare CRBP & APYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRBP | APYX |
|---|---|---|
| Founded | 2009 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.8M | 156.7M |
| IPO Year | 2014 | 1995 |
| Metric | CRBP | APYX |
|---|---|---|
| Price | $7.63 | $3.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $50.29 | $7.00 |
| AVG Volume (30 Days) | ★ 138.7K | 117.5K |
| Earning Date | 01-01-0001 | 04-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.31 | 19.40 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,822,272.00 | N/A |
| Revenue This Year | N/A | $9.36 |
| Revenue Next Year | $220.00 | $6.70 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 97.62 | N/A |
| 52 Week Low | $4.64 | $0.83 |
| 52 Week High | $20.56 | $4.50 |
| Indicator | CRBP | APYX |
|---|---|---|
| Relative Strength Index (RSI) | 43.45 | 40.31 |
| Support Level | $6.73 | $3.30 |
| Resistance Level | $8.43 | $4.40 |
| Average True Range (ATR) | 0.47 | 0.27 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 38.50 | 6.52 |
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.